Betoptic S Shortage: What Providers and Prescribers Need to Know in 2026

Betoptic S (betaxolol hydrochloride ophthalmic suspension 0.25%) occupies a specific clinical niche: it is the only cardioselective ophthalmic beta blocker available in a suspension formulation in the U.S. market. For patients with reactive airway disease, significant cardiovascular sensitivity, or tolerance issues with other beta blocker eye drops, Betoptic S may be the only appropriate option in its class.

Yet providers are increasingly hearing from patients who cannot fill their Betoptic S prescription. This guide outlines what's driving these availability gaps, clinical strategies for managing affected patients, and tools you can offer to help patients locate their medication.

Understanding the Current Availability Landscape

As of 2026, Betoptic S is not on the FDA's official drug shortage list. However, its brand-only status (no FDA-approved generic suspension exists), combined with high retail cost ($400–$521 per 10 mL), limited pharmacy stocking, and common insurance barriers, creates real-world access problems that do not rise to the level of a formal shortage declaration but still disrupt patient care.

Patients on long-term Betoptic S therapy — many of whom are elderly with Medicare or fixed-income constraints — are particularly vulnerable. The drug's limited distribution footprint means a single stocking gap at their preferred pharmacy can interrupt treatment.

Why Betoptic S Still Has a Role in 2026

While prostaglandin analogs have become the predominant first-line agents for open-angle glaucoma and ocular hypertension, beta blockers retain clinical relevance as second-line agents and in specific patient populations. Betaxolol's beta-1 selectivity makes it the preferred ophthalmic beta blocker when:

• The patient has asthma, COPD, or significant reactive airway disease and cannot tolerate nonselective agents (timolol, levobunolol)
• Prostaglandin analogs are contraindicated or poorly tolerated (uveitic glaucoma, cystoid macular edema risk, cosmetic concerns)
• Add-on therapy is needed and the patient cannot tolerate brimonidine or topical CAIs
• Patient comfort with the suspension formulation has been a key factor in medication adherence

Clinical Alternatives When Betoptic S Is Unavailable

When Betoptic S cannot be obtained in a timely manner, the following substitutions may be appropriate — always individualized to patient comorbidities and prior response:

• Betaxolol ophthalmic solution 0.5% (generic): Same molecule, widely available, significantly less expensive (~$21 with GoodRx). Note increased ocular discomfort vs. suspension — may reduce adherence in sensitive patients.
• Timolol maleate 0.25–0.5%: Nonselective beta blocker, greater IOP reduction but contraindicated with reactive airway disease or significant bradycardia. Widely available and inexpensive.
• Brimonidine tartrate 0.1–0.2%: Alpha-2 agonist appropriate for patients with beta blocker contraindications. BID–TID dosing. Risk of ocular allergy with long-term use.
• Latanoprost or other prostaglandin analogs: If the patient is not already on a prostaglandin analog as monotherapy or is switching from beta blocker monotherapy, prostaglandin analogs offer robust IOP reduction with once-daily dosing.
• Dorzolamide or brinzolamide: Topical CAIs are effective add-on agents and can be appropriate when patients cannot use other drug classes.

Navigating Insurance and Prior Authorization

Many commercial and Medicare Part D plans require prior authorization or step therapy before covering Betoptic S. When submitting prior authorization requests, clinical justification should emphasize:

• Patient's specific cardiorespiratory comorbidities that necessitate a cardioselective agent
• Documented intolerance to nonselective alternatives if applicable
• Established IOP control on Betoptic S and adherence advantages of the suspension formulation

Helping Your Patients Locate Betoptic S

Recommending that patients call individual pharmacies is often insufficient — many patients, particularly older adults, face significant barriers to making multiple calls. Directing patients to medfinder for providers offers a more efficient path: medfinder calls pharmacies on the patient's behalf to identify which ones have the medication in stock, then texts results to the patient.

Key Clinical Takeaways

• Betoptic S is not in a formal FDA shortage but remains difficult to obtain in many markets in 2026
• Its cardioselective beta-1 profile is irreplaceable for asthmatic and COPD patients who need an ophthalmic beta blocker
• The generic betaxolol solution is the nearest pharmacologically equivalent substitute when the suspension cannot be found
• Prior authorization documentation should emphasize clinical necessity for the cardioselective formulation
• Directing patients to medfinder can reduce access delays and support treatment continuity